位置：成果数据库 > 期刊 > 期刊详情页
RARalpha2 expression confers myeloma stem cell features.
  • ISSN号：0006-4971
  • 期刊名称：Blood
  • 时间：2013.8.22
  • 页码：1437-1447
  • 相关项目：维甲酸受体α作为靶向治疗骨髓瘤干细胞的新靶点的研究
作者： Xia, Jiliang|Wang, He|Zhou, Wen|Zhou, Yi|Das, Satyabrata|Gu, Zhimin|Levasseur, Dana|Zhan, Fenghuang|Tricot, Guido|
同期刊论文项目
维甲酸受体α作为靶向治疗骨髓瘤干细胞的新靶点的研究
期刊论文 17
同项目期刊论文
[Myeloma cancer stem cells:the new target for multiple myeloma].
Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized
多发性骨髓瘤的诊断进展与分期
Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomize
Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.
Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS
Smoldering multiple myeloma
Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor v
ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signature
Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma.
Down-regulation of 11beta-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukem
蛋白酶体抑制剂治疗多发性骨髓瘤现状
Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells
Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism